intracranial aneurysm
Conditions
Interventions
Case series:stent implantation
Sponsors
Changhai Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Subarachnoid hemorrhage clearly diagnosed by CT or lumbar puncture within 28 days after onset; 2. Subject aged 18 to 75 years old; 3. For intracranial ruptured wide-neck aneurysms confirmed by DSA, the aneurysmal neck width >=4 mm or body-neck ratio 6 months; 6. Subjects or their family members agree to sign the informed consent.
Exclusion criteria
Exclusion criteria: 1. Patients with intracranial ruptured aneurysm with intracranial hematoma; 2. The subject has other intracranial vascular malformations, such as AVM and AVF; 3. Aneurysms associated with blood vesicles, dissection, fusiform, traumatic, infectious or cerebrovascular malformations; 4. Ruptured aneurysms already treated; 5. Aneurysms treated with simple stent implantation, aneurysm bearing artery occlusion or other non-detachable coil embolization materials; 6. Subjects with malignant tumors in intracranial or other parts of the body; 7. Disabled before stroke, which may interfere with the functional outcome assessment 1 year after surgery, namely mRS > 2; 8. People with severe mental illness are unable to communicate when diagnosing their illness; 9. Patients with poor systemic condition, life expectancy less than 1 year or poor physical condition, unable to tolerate general anesthesia or aneurysm surgery; 10. Patients who cannot receive antiplatelet aggregation or anticoagulation therapy, or have abnormal coagulation function; 11. Patients with contrast agent allergy or intolerance; 12. Subjects who have participated in clinical trials of other drugs or medical devices before being enrolled and have not reached the time limit of the main study endpoint; 13. The investigator considers it inappropriate to participate in or continue to participate in this clinical trial; 14. Patients who did not receive complete follow-up; 15. Pregnant women and women who are planning to become pregnant during follow-up; 16. A history of drug abuse or a patient with drug abuse during follow-up; 17. Major surgeries planned within 30 days of inclusion or 90 days after inclusion
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| safety; | — |
Countries
China
Contacts
Public ContactQiao Zuo
Changhai Hospital, Naval Medical University, PLA
Outcome results
None listed